Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variantKirsten E. Lyke, Anna Wald, Lisa A. Jackson et al.|Cell Reports Medicine|2022Cited by 168
A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunizationDavid I. Bernstein, A. Louis Bourgeois, Marcela F. Pasetti et al.|Vaccine|2018Cited by 36
Safety and Immunogenicity of Influenza A/H5N8 Virus Vaccine in Healthy Adults: Durability and Cross-reactivity of Antibody ResponsesKathleen M. Neuzil, James E. Crowe, Evan J. Anderson et al.|Clinical Infectious Diseases|2023Cited by 17
The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boostNoemia S. Lima, Anna P. Wald, Lauren McCormick et al.|Science Translational Medicine|2026Cited by 0